S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
NASDAQ:ZYNE

Zynerba Pharmaceuticals - ZYNE Stock Forecast, Price & News

$0.66
+0.03 (+4.74%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.58
▼
$0.68
50-Day Range
$0.50
▼
$0.66
52-Week Range
$0.49
▼
$2.94
Volume
465,525 shs
Average Volume
248,156 shs
Market Capitalization
$30.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Zynerba Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
1,559.4% Upside
$11.00 Price Target
Short Interest
Healthy
0.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.01mentions of Zynerba Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$54,328 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.86) to ($0.68) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

307th out of 1,054 stocks

Pharmaceutical Preparations Industry

143rd out of 517 stocks

See Top Rated MarketRank™ Stocks Here

ZYNE stock logo

About Zynerba Pharmaceuticals (NASDAQ:ZYNE) Stock

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Receive ZYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ZYNE Stock News Headlines

January 27, 2023 | marketwatch.com
Fibromyalgia Treatment Drug Market 2023 : Profiling Key Players, Value Estimation and Analysis by Recent Trends to 2028
January 26, 2023 | americanbankingnews.com
Insider Selling: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Chairman Sells 35,453 Shares of Stock
January 28, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
January 26, 2023 | americanbankingnews.com
Insider Selling: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) CFO Sells 17,769 Shares of Stock
January 26, 2023 | americanbankingnews.com
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) President Terri B. Sebree Sells 24,661 Shares
January 12, 2023 | msn.com
What's The Role Of The Endocannabinoid System In Fragile X Syndrome? How Can Cannabidiol Treatment Help? New Paper
January 11, 2023 | finance.yahoo.com
Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
January 10, 2023 | forbes.com
Zynerba Pharmaceuticals
January 28, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
December 21, 2022 | proactiveinvestors.com
Zynerba Pharmaceuticals revises timeline for release of topline results from Phase 3 RECONNECT trial of Zygel in Fragile X syndrome
December 21, 2022 | finance.yahoo.com
Zynerba Pharmaceuticals delays data on genetic disorder drug study
December 21, 2022 | finance.yahoo.com
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
December 21, 2022 | finance.yahoo.com
UPDATE 2-Zynerba delays genetic disorder drug data on enrollment challenge
December 5, 2022 | msn.com
CBD-Based Zygel Helps With Anxiety-Related & Behavioral Symptoms In 22q11.2 Deletion Syndrome, Phase 2 Trial Reveals
December 5, 2022 | finance.yahoo.com
Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology
November 29, 2022 | finance.yahoo.com
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology
November 28, 2022 | proactiveinvestors.com
Zynerba Pharmaceuticals' Zygel shows meaningful behavioral symptom treatment progress in Fragile X patients in phase 3 trial
November 28, 2022 | finance.yahoo.com
Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders
November 15, 2022 | proactiveinvestors.com
Zynerba Pharmaceuticals granted orphan drug designation by EC for Zygel active ingredient to treat 22q
November 15, 2022 | finance.yahoo.com
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome
November 14, 2022 | msn.com
Zynerba Pharmaceuticals R&D Expenses For Q3 Reach $5M, Here Are The Details
November 14, 2022 | proactiveinvestors.com
Zynerba ends 3Q with robust $55.9M cash runway to advance its Zygel CBD Gel for Fragile X Syndrome
November 14, 2022 | finance.yahoo.com
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
November 3, 2022 | proactiveinvestors.com
Zynerba Pharmaceuticals boosts intellectual property portfolio with new patents for Zygel
November 2, 2022 | proactiveinvestors.com
Zynerba Pharmaceuticals gets another US Patent for its transdermal cannabidiol product candidate, Zygel
November 2, 2022 | proactiveinvestors.com
Zynerba Pharmaceuticals gets another US Patent for its transdermal cannabidiol product, Zygel
November 2, 2022 | finance.yahoo.com
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome
See More Headlines
Receive ZYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ZYNE Company Calendar

Last Earnings
11/14/2022
Today
1/28/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZYNE
CUSIP
N/A
CIK
1621443
Web
www.zynerba.com
Phone
(484) 581-7505
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+1,559.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.87)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-37,310,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-58.25%
Return on Assets
-50.31%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.45
Quick Ratio
6.45

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.72 per share
Price / Book
0.39

Miscellaneous

Outstanding Shares
45,750,000
Free Float
40,931,000
Market Cap
$30.33 million
Optionable
Optionable
Beta
1.64

Key Executives

  • Armando Anido
    Chairman & Chief Executive Officer
  • Terri B. Sebree
    President
  • James E. Fickenscher
    Chief Financial Officer & VP-Corporate Development
  • Nancy Tich
    Vice President-Clinical
  • Carol B. O'Neill
    Vice President-Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ZYNE Stock - Frequently Asked Questions

Should I buy or sell Zynerba Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZYNE shares.
View ZYNE analyst ratings or view top-rated stocks.

What is Zynerba Pharmaceuticals' stock price forecast for 2023?

3 Wall Street analysts have issued 12-month target prices for Zynerba Pharmaceuticals' stock. Their ZYNE share price forecasts range from $11.00 to $11.00. On average, they expect the company's share price to reach $11.00 in the next year. This suggests a possible upside of 1,559.4% from the stock's current price.
View analysts price targets for ZYNE or view top-rated stocks among Wall Street analysts.

How have ZYNE shares performed in 2023?

Zynerba Pharmaceuticals' stock was trading at $0.53 at the beginning of the year. Since then, ZYNE stock has increased by 25.1% and is now trading at $0.6629.
View the best growth stocks for 2023 here.

When is Zynerba Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our ZYNE earnings forecast.

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) released its quarterly earnings data on Monday, November, 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.01.

What other stocks do shareholders of Zynerba Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU).

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an IPO on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

How do I buy shares of Zynerba Pharmaceuticals?

Shares of ZYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zynerba Pharmaceuticals' stock price today?

One share of ZYNE stock can currently be purchased for approximately $0.66.

How much money does Zynerba Pharmaceuticals make?

Zynerba Pharmaceuticals (NASDAQ:ZYNE) has a market capitalization of $30.33 million. The company earns $-37,310,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis.

How can I contact Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The official website for the company is www.zynerba.com. The company can be reached via phone at (484) 581-7505 or via email at investorrelations@zynerba.com.

This page (NASDAQ:ZYNE) was last updated on 1/28/2023 by MarketBeat.com Staff